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Introduction {#jdi12182-sec-0001}
============

The goal of treating type 2 diabetes mellitus is to prevent complications caused by chronic hyperglycemia, and it is important to maintain good glycemic control over a long period[1](#jdi12182-bib-0001 jdi12182-bib-0002 jdi12182-bib-0003 jdi12182-bib-0004 jdi12182-bib-0005){ref-type="ref"}. Japanese patients with type 2 diabetes mellitus are characterized by lower early phase insulin secretion after meal ingestion, hence treatment of Japanese patients is focused on activation of insulin secretion with sulfonylureas (SUs)[6](#jdi12182-bib-0006 jdi12182-bib-0007){ref-type="ref"}. Before the introduction of dipeptidyl peptidase‐4 (DPP‐4) inhibitors, sulfonylureas were most often used as monotherapy in Japan[8](#jdi12182-bib-0008){ref-type="ref"}. Sitagliptin is a new hypoglycemic agent[9](#jdi12182-bib-0009 jdi12182-bib-0010 jdi12182-bib-0011 jdi12182-bib-0012 jdi12182-bib-0013){ref-type="ref"}, which is often administered as add‐on therapy to patients showing inadequate glycemic control with SU treatment[14](#jdi12182-bib-0014 jdi12182-bib-0015 jdi12182-bib-0016 jdi12182-bib-0017 jdi12182-bib-0018 jdi12182-bib-0019 jdi12182-bib-0020 jdi12182-bib-0021 jdi12182-bib-0022){ref-type="ref"}. In the present study, we investigated the hypoglycemic effect of sitagliptin, and its durability in patients receiving combination therapy with a SU and sitagliptin.

Materials and Methods {#jdi12182-sec-0002}
=====================

The present study enrolled 162 patients (Table [1](#jdi12182-tbl-0001){ref-type="table-wrap"}) with type 2 diabetes mellitus who had inadequate glycemic control despite oral SU‐based therapy (glimepiride *n* = 60, gliclazide *n* = 52 and glibenclamide *n* = 50) and received add‐on treatment with sitagliptin for 1 year. Other concomitant drugs included metformin (*n* = 99), pioglitazone (*n* = 47) and an α‐glucosidase inhibitor (*n* = 7).

###### Clinical characteristics of the hemoglobin A1c elevated and hemoglobin A1c non‐elevated groups and *P*‐values

                            Total         HbA1c‐elevated group   HbA1c‐non‐elevated group   *P*‐value
  ------------------------- ------------- ---------------------- -------------------------- -----------
  *n*                       162           57                     105                        
  Age (years)               65.6 ± 10.0   63.9 ± 9.8             66.5 ± 10.0                NS
  Sex (male/female)         98/64         30/27                  68/37                      NS
  Baseline BMI (kg/m^2^)    24.4 ± 4.0    24.5 ± 3.9             24.3 ± 3.9                 NS
  Duration of DM (years)    13.2 ± 8.4    12.3 ± 7.7             13.8 ± 8.7                 NS
  ΔBW0_24 week (kg)         0.2 ± 1.2     0.4 ± 1.5              0.1 ± 0.7                  NS
  ΔBW24_52 week (kg)        0.3 ± 1.4     0.9 ± 1.8              0.0 ± 0.9                  \<0.01
  Glimepiride (mg/day)      1.7 ± 1.2     1.6 ± 1.0              1.8 ± 1.2                  NS
  Gliclazide (mg/day)       34.4 ± 19.4   33.1 ± 17.6            35.0 ± 20.1                NS
  Glibenclamide (mg/day)    3.5 ± 2.2     4.6 ± 2.1              2.9 ± 1.9                  \<0.01
  Metformin                 99            37 (64.9%)             62 (59.0%)                 NS
  Pioglitazone              47            17 (29.8%)             30 (28.6%)                 NS
  α‐Glucosidase inhibitor   7             3 (5.3%)               4 (3.8%)                   NS

ΔBW0_24 week, difference of bodyweight between 0 and 24 weeks; ΔBW24_52 week, difference of bodyweight between 24 and 52 weeks; BMI, body mass index; DM, diabetes mellitus; HbA1c, hemoglobin A1c; NS, not significant.
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Patients were divided into a hemoglobin A1c (HbA1c)‐elevated group consisting of those with an increase of HbA1c by 0.4% or more in week 52 compared with week 24, and a HbA1c‐non‐elevated group consisting of the remaining patients. Logistic regression analysis was carried out to investigate the factors involved in the increase of blood glucose during the later part of the treatment period in the patients taking glibenclamide, glimepiride or gliclazide. The factors assessed were the clinical characteristics of the patients (age, sex, body mass index, duration of diabetes), the change of bodyweight from week 24 to week 52, the dose of glibenclamide and the use of other medications.

The primary end‐point was the HbA1c level. The values of HbA1c in the present study were converted and expressed by National Glycohemoglobin Standardization Program values[23](#jdi12182-bib-0023){ref-type="ref"}.

All analyses were carried out using SPSS version 19 for Windows (SPSS, Chicago, IL, USA). Data on HbA1c and bodyweight were processed by one‐way analysis of variance ([anova]{.smallcaps}). The Mann--Whitney *U*‐test was used for comparison of the HbA1c‐elevated group with the non‐elevated group. Results are presented as the mean ± standard deviation, and *P *\<* *0.05 was considered significant.

The present retrospective observational study was carried out in accordance with the provisions of the Helsinki Declaration. Approval was obtained from the ethics committee of the Kansai Electric Power Hospital, and written informed consent was obtained from all patients.

Results {#jdi12182-sec-0003}
=======

The mean HbA1c was 7.77 ± 0.73% at the start of treatment with sitagliptin, and it decreased significantly to 7.45 ± 0.71% after 4 weeks of treatment and to 7.25 ± 0.75% in week 52, suggesting that the improvement of glycemic control was maintained during 12 months of treatment (Figure [1](#jdi12182-fig-0001){ref-type="fig"}a). However, the HbA1c level became slightly higher during the later part of the treatment period, and HbA1c was significantly higher in week 52 than it was between weeks 16 and 44 ([anova]{.smallcaps},*P *\< 0.01). The mean bodyweight showed no significant change during 12 months (Figure [1](#jdi12182-fig-0001){ref-type="fig"}b).

![Profile of (a) hemoglobin A1c (HbA1c) and (b) bodyweight (BW) over 52 weeks. Analysis of variance vs week 0 \*\**P *\< 0.01, vs week 52 ††*P *\< 0.01.](jdi-5-445-g1){#jdi12182-fig-0001}

To analyze the factors related to the slight increase of HbA1c in the later part of the treatment period, patients were divided into a HbA1c‐elevated group (*n* = 57) and a HbA1c non‐elevated group (*n* = 105; Figure [2](#jdi12182-fig-0002){ref-type="fig"}). The characteristics of these two groups are compared in Table [1](#jdi12182-tbl-0001){ref-type="table-wrap"}; there were significant differences regarding the change of bodyweight from week 24 to week 52 and the dose of glibenclamide. There was no significant difference in the change of bodyweight from week 0 to week 24. There was no significant difference in the dose of the other SUs or in the use of medications other than SUs between the two groups. When logistic regression analysis was carried out in the glibenclamide group to determine the factors related to poor glycemic control, it was found that the difference of bodyweight between 24 and 52 weeks (ΔBW24_52 week) and the dose of glibenclamide were significant (Table [2](#jdi12182-tbl-0002){ref-type="table-wrap"}). Thus, greater weight gain from week 24 to week 52 and a higher dose of glibenclamide were associated with a larger increase of HbA1c, but the age, sex and baseline body mass index were not significant factors. Logistic regression analysis carried out in the glimepiride or gliclazide groups showed that ΔBW24_52 week was the only significant factor in both groups, whereas the dose of glimepiride or gliclazide was not significant.

###### Factors influencing the durability of combined sitagliptin and glibenclamide therapy according to logistic regression analysis

  Independent variable    Partial regression coefficient   *P*‐value
  ----------------------- -------------------------------- -----------
  ΔBW24_52 week           −0.829                           \<0.05
  Dose of glibenclamide   −0.449                           \<0.05

ΔBW24_52 week, difference of bodyweight between 24 and 52 weeks.
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![Profile of hemoglobin A1c (HbA1c) in a HbA1c‐elevated group and a HbA1c non‐elevated group over 52 weeks.](jdi-5-445-g2){#jdi12182-fig-0002}

Discussion {#jdi12182-sec-0004}
==========

In the present study, a significant decrease of blood glucose was achieved that persisted throughout the study period with no significant change of bodyweight. Comparison between the groups of patients showing poorer and better durability of therapeutic efficacy showed a significant increase in bodyweight from week 24 to week 52 in the group with the elevated HbA1c. We also found that patients in the poorer durability group received a higher dose of glibenclamide. Thus, weight gain from week 24 to week 52 and the dose of glibenclamide were factors significantly related to poorer glycemic control. As previous reports have suggested that sitagliptin has no effect on bodyweight, the cause of the weight gain in the present study might be due to inadequate diet and/or exercise therapy[11](#jdi12182-bib-0011 jdi12182-bib-0012 jdi12182-bib-0013 jdi12182-bib-0020){ref-type="ref"}. Indeed, Tajiri *et al*.[24](#jdi12182-bib-0024){ref-type="ref"} reported that blood glucose levels were likely to increase over time in patients on sitagliptin therapy with low lifestyle scores, which is consistent with our present results. Seasonal changes of glycemic control are often observed during the treatment of diabetes, and weight gain might have been related to such seasonal changes. Therefore, when sitagliptin is administered as add‐on therapy to patients who have developed secondary failure of SU‐based treatment, it is important to ensure that diet and exercise therapy are adequate to prevent weight gain in order to maintain glycemic control over a long period[16](#jdi12182-bib-0016 jdi12182-bib-0023){ref-type="ref"}.

It is curious that only a higher dose of glibenclamide was associated with poor glycemic control independently of weight gain. In contrast, the doses of glimepiride and gliclazide were similar in both groups, and these drugs were used at relatively low doses compared with the glibenclamide‐treated group. Logistic regression analysis showed that the dose of glimepiride or gliclazide was not a significant factor. The incidence of so‐called secondary failure has been reported to differ among SU drugs[25](#jdi12182-bib-0025 jdi12182-bib-0026){ref-type="ref"}. Both Harrower[25](#jdi12182-bib-0025){ref-type="ref"} and Satoh *et al*.[26](#jdi12182-bib-0026){ref-type="ref"} reported that the incidence of secondary failure was higher for glibenclamide than gliclazide. The SU drugs show differences of various properties[27](#jdi12182-bib-0027 jdi12182-bib-0028 jdi12182-bib-0029 jdi12182-bib-0030){ref-type="ref"}, and it is not yet clear which properties of SU drugs have an influence on the incidence of secondary failure[25](#jdi12182-bib-0025 jdi12182-bib-0026){ref-type="ref"}. The results of the present study are likely to have been influenced by differences in the rate of secondary failure among SU drugs.

DPP‐4 inhibitors reduce blood glucose levels by increasing insulin secretion by an incretin effect. Accordingly, it is likely that endogenous insulin secretion was lower in the patients treated with higher doses of glibenclamide than in those receiving lower doses of this drug. Further studies are required to resolve these issues.

In summary, we analyzed the profile of glycemic control in patients receiving combination therapy with SUs and sitagliptin. The present results show that avoiding both weight gain and high‐dose glibenclamide therapy can contribute to the maintenance of better glycemic control.

However, it is unclear whether other factors also contributed to the decrease in efficacy of DPP‐4 inhibitor therapy or the secondary failure of DPP‐4 inhibitor treatment in the present study, hence further investigations are required.
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